Synopsis

This study examines orally administered naltrexone-bupropion combination pharmacotherapy for people with methamphetamine use disorder in an outpatient setting. We will recruit 20 participants for a 12-week open-label clinical trial, with a follow-up 4 weeks after completion. Participants will receive a combination of naltrexone hydrochloride 40mg and bupropion 450mg per day for 12 weeks, with a 5-day taper at the beginning and end of the treatment period.

The primary outcomes are safety and feasibility to make sure the medication is safe to use, and that it is feasible to give the medication in this way.

Recruitment for this study is now closed.

Investigators

Prof Nadine Ezard

SVHS/UNSW/National Centre for Clinical Research on Emerging Drugs

Dr Krista Siefried

UNSW/National Centre for Clinical Research on Emerging Drugs

Dr Carl Moller

UNSW

Dr Liam Acheson

SVHS/UNSW/Alcohol and Drug Service/National Drug and Alcohol Research Centre

Dr Jonathan Brett

SVHS/Alcohol and Drug Service/Clinical Pharmacology and Toxicology

Dr Michael Christmass

Next Step Drug and Alcohol Services/Drug and Alcohol Services

Dr Brendan Clifford

SVHS/UNSW/Alcohol and Drug Service/National Drug and Alcohol Research Centre

Prof Adrian Dunlop

Hunter New England LHD/Drug and Alcohol Clinical Services

Prof Paul Haber

Sydney Local Health District and University of Sydney

Prof Nicholas Lintzeris

South East Sydney LHD/Drug and Alcohol Services

Prof Kirsten Morley

University of Sydney

Prof Steve Shoptaw

The University of California, Los Angeles/Family Medicine/Psychiatry and Biobehavioural Sciences

Prof Madhukar Trivedi

University of Texas Southwestern Medical Center

A/Prof Didier Jutras-Aswad

Centre Hospitalier de l’Université de Montréal